Graeme Fraser

Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT.

Société Régionale d'Investissement de Wallonie SA (SRIW) is a private equity & venture capital firm , a subsidiary of Region of Wallonia founded in 1979. Société Régionale d'Investissement de Wallonie SA is headquartered in Liege, Belgium.

Altamar Private Equity SGIIC SA (Altamar Private Equity) is a private equity arm of Altamar Capital Partners SL founded in 2004. The firm is headquartered in Spain with additional offices in New York and Santiago de Chile.

Henogen SA develops and manufactures biopharmaceuticals. The company was founded on November 19, 1999 and is headquartered in Charleroi, Belgium.

Okairos AG develops preventive and therapeutic vaccines against human chronic infectious diseases. Its products include genetic vaccines, adenovirus vector platform, and proprietary cell line. The company was founded by Riccardo Cortese, Alfredo Nicosia, and Antonella Folgori in 2007 and is headquartered in Basel, Switzerland.

PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Part of Elia Group SA/NV, Elia Asset SA engages in power generation and distribution services. The company is based in Brussels, Belgium. The Belgian company was founded in 2001. The CEO is Christiaan Peeters.

Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria.

The European Vaccine Initiative manufactures vaccines. The private company is based in London, UK.

Q-Biologicals NV operates as a bio pharma contract development and manufacturing organization. It provides process development and bio manufacturing services to customers in the biopharmaceutical industry. The company was founded in 2011 and is headquartered in Ghent, Belgium.

20Med Therapeutics BV operates as a biomedical company. It focuses on the development of biodegradable materials for biomedical applications and multifunctional nanosystems for controlled drug and gene delivery. The company was founded by Johan F. J. Engbersen in 2011 and is headquartered in Enschede, the Netherlands.

Bridge2Health SA provides biomedical translational research services. It offers services to the clinicians, basic researchers and pharmaceutical industries. The firm also provides blueprint for biobank query and retrieval between universities. The company was founded in September 2012 and is headquartered in Liege, Belgium.

iSTAR Medical SA develops innovative ophthalmic implants. Its products include MINIject, STARflo and STAR Material. The company was founded by Michel Alvarez in 2011 and is headquartered in Wavre, Belgium.

Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium.

Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain.

Fund+ is an independent Venture Capital firm founded in 2015. The firm is headquartered in Leuven, Belgium.

Aelix Therapeutics SL researches and develops therapies for HIV. It develops therapeutic vaccines and immunotherapies to treat HIV infection. The firm is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was founded by Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Jordi Naval is headquartered in Barcelona, Spain.

eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium.

Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland.

Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France.

PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France.

DreamJet Participations SA operates as a holding company, with interest in the provision of air transportation services. The company is headquartered in Le Bourget, France.

Pharmafluidics NV develops micro chip liquid chromatography cartridges for analysis of complex biological samples. The company was founded by Wim De Malsche, Joeri Denayer, Gert Desme and Paul Godelieve Jacobs in 2010 and is headquartered in Ghent, Belgium.

DIM3 SA develops decision support application software and medical devices. The firm offers Scorso, an app for the screening and follow-up of disease-related malnutrition; Nutrow, a decision support software for an optimization of clinical nutrition; and Biocorder, a connected clinical mobile assistant. The company was founded by Jean Claude Havaux on September 23, 2004 and is headquartered in Liege, Belgium.

Ncardia SA engages in drug discovery research and development. Its cardiac products encompass hiPSC-derived Pluricyte, Cardiomyocytes, Cor.4U cardiomyocytes and vCor.4U ventricular cardiomyocytes and FibroCor.4U cardiac fibroblasts. The company is headquartered in Gosselies, Belgium.

EPICS Therapeutics SA engages in the development of therapeutic solutions for cancer. The company was founded by Jean Combalbert, Alain Parthoens and Francois Fuks on February 20, 2018 and is headquartered in Charleroi, Belgium.

Part of Elia Group SA/NV, Elia Transmission Belgium NV is a transmission system operator that operates at a European level. Based in Brussels, BE, Elia Transmission Belgium is leading the way in the energy revolution by developing diverse, sustainable, and reliable electrical systems on land and at sea. The Belgian company ensures the security of supply, serves its customers, and protects the safety of its personnel and subcontractors. Christiaan Peeters has been the CEO of the company since 2015.

Armeos NV is a Belgian company that specializes in the protection and management of harmful organizations. The company is based in Nivelles, Belgium, and has subsidiaries in Belgium, France, and Poland. The company brings nature back into balance when it requires assistance. Armeos was founded in 2017, and the CEOs are Jean Klimis and Pierre Klimis.

Exevir Bio BV is engaged in biotechnology services. The company is headquartered in Zwijnaarde, Belgium.

NeuVasQ Biotechnologies SA develops pharmaceutical products to treat neurological disorders by repairing neurovascular function. The company is based in Gosselies, Belgium. The Belgian company was founded in 2021 by Benoit Vanhollebeke.

Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland.

LeukoCare AG develops protein stabilization and protection solutions. The firm specializes in the development of protein stabilization and protection solutions for biopharmaceuticals, vaccines, medical devices, and diagnostics technologies. Its service areas encompass technology licensing, prototyping and product development, clinical registration, biological and chemical testing, and consulting. The company was founded by Martin Scholz in 2001 and is headquartered in Munich, Germany.